WO2005104834A3 - Pain-associated gene pnpg5 - Google Patents

Pain-associated gene pnpg5 Download PDF

Info

Publication number
WO2005104834A3
WO2005104834A3 PCT/US2005/012693 US2005012693W WO2005104834A3 WO 2005104834 A3 WO2005104834 A3 WO 2005104834A3 US 2005012693 W US2005012693 W US 2005012693W WO 2005104834 A3 WO2005104834 A3 WO 2005104834A3
Authority
WO
WIPO (PCT)
Prior art keywords
pain
pnpg5
gene
associated gene
invention further
Prior art date
Application number
PCT/US2005/012693
Other languages
French (fr)
Other versions
WO2005104834A2 (en
Inventor
Lillian W Chiang
Jiefei Tong
Original Assignee
Euro Celtique Sa
Lillian W Chiang
Jiefei Tong
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa, Lillian W Chiang, Jiefei Tong filed Critical Euro Celtique Sa
Publication of WO2005104834A2 publication Critical patent/WO2005104834A2/en
Publication of WO2005104834A3 publication Critical patent/WO2005104834A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention provides a gene, designated herein as “PNPG5”, that is associated with pain. The invention further provides the use of PNPG5 gene and its corresponding protein to diagnose a pain state in a cell or tissue and to screen for novel therapeutic compounds useful for treating pain as well as for other indications. The present invention further provides a novel pain-associated molecular complex, comprising PNPG5, and at least one other pain-associated transmembrane protein such as PNPG2.
PCT/US2005/012693 2004-04-14 2005-04-13 Pain-associated gene pnpg5 WO2005104834A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US56256304P 2004-04-14 2004-04-14
US60/562,563 2004-04-14
US64764205P 2005-01-26 2005-01-26
US60/647,642 2005-01-26

Publications (2)

Publication Number Publication Date
WO2005104834A2 WO2005104834A2 (en) 2005-11-10
WO2005104834A3 true WO2005104834A3 (en) 2006-11-16

Family

ID=35242198

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/012693 WO2005104834A2 (en) 2004-04-14 2005-04-13 Pain-associated gene pnpg5

Country Status (1)

Country Link
WO (1) WO2005104834A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20060089A0 (en) * 2006-01-30 2006-01-30 Heikki Matti Eemeli Rauvala Treatment of behavioral disorders
WO2013082288A1 (en) * 2011-11-29 2013-06-06 The Regents Of The University Of California Glucorticoid receptor gene nr3c1 methylation in irritable bowel syndrome and other stress disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KUJA-PANULA ET AL.: "AMIGO, a transmembrane protein implicated in axon tract development, defines a novel protein family with leucine-rich repeats", JCB, vol. 160, no. 6, 17 March 2003 (2003-03-17), pages 963 - 973, XP003011304, DOI: doi:10.1083/jcb.200209074 *

Also Published As

Publication number Publication date
WO2005104834A2 (en) 2005-11-10

Similar Documents

Publication Publication Date Title
WO2004089396A3 (en) Anti-fungal peptidomimetics
MX2007010560A (en) Roflumilast for the treatment of diabetes mellitus.
EP2361934A3 (en) Hepatocyte growth factor (HGF) binding proteins
WO2005014035A3 (en) Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
WO2007009894A3 (en) Peptides for use in the treatment of obesity
WO2007143098A8 (en) Hepatocyte growth factor (hgf) binding proteins
WO2004074434A3 (en) Methods and compositions for administering therapeutic and diagnostic agents
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
WO2008030273A3 (en) Compositions and methods for diagnosis and treatment of type 2 diabetes
WO2008070672A3 (en) Compositions and methods to treat cancer with cupredoxins and cpg rich dna
WO2008055491A3 (en) Diagnosis and risk assessment of pancreatic diabetes using mr-proadm
WO2006101387A3 (en) Method for interfering with blood coagulation by modulating cross-beta structures fibril formation
ATE511645T1 (en) TEST METHOD FOR DETECTING ANTIBODIES AGAINST LYSOSOME ENZYMES
EP2386639A3 (en) Modified pore-forming protein toxins and use thereof
WO2004043223A3 (en) Compositions and methods for the diagnosis and treatment of sepsis
MXPA06012143A (en) Arylsulfonamides and uses related thereto.
WO2007038264A3 (en) Gapr-1 methods
WO2004033660A3 (en) Gene expression profiling from ffpe samples
WO2005124358A3 (en) Diagnosis and treatment of siglec-6 associated diseases
EP2083018A3 (en) Compositions and methods relating to STOP-1
TW200738255A (en) Methods of regulating renalase (Monoamine Oxidase C)
WO2003101948A3 (en) Agents for imaging and diagnostic methods using them
WO2005104834A3 (en) Pain-associated gene pnpg5
UA107177C2 (en) Immunogenic composition of CVC2 and the method of preparation of such composition
WO2006063009A3 (en) Diagnosis of hyperinsulinemia and type ii diabetes and protection against same based on proteins differentially expressed in serum

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase